Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Not-For-Profit Partnership With Eli Lilly and Company for TB Early Phase Drug Discovery

The Partnership

In 2007, as part of their philanthropic effort in multidrug-resistance tuberculosis, Eli Lilly and Company announced The Lilly TB Drug Discovery Initiative. This unique endeavor is designed to accelerate discovery and development of new drugs to fight TB. The ultimate aim is to make treatment of TB more effective, accessible, and affordable.

The partnership will be based in Seattle, Washington, at the Infectious Disease Research Institute (IDRI). Partners include

  • Eli Lilly & Company
  • Afya World Medicines
  • Infectious Disease Research Institute
  • Jubilant Biosys
  • Merck and Company
  • Seattle Biomedical Research Institute
  • University of Washington Department of Global Health


  • Integrate key scientific disciplines needed for sustained discovery of new medicines to treat TB
  • Bring together leading scientists to share capabilities and expertise in TB research and drug discovery
  • Make medicinal chemistry and associated technologies readily available to TB researchers
  • Enable new drug candidates to enter the research and development pipeline
  • Enhance the early stage TB pipeline for developers such as the Global Alliance for TB Drug Development—a not-for-profit, product development partnership

What You Can Do

If you have candidate compounds or validated targets that may be suitable for TB drug development, contact Dr. Gail Cassell at Lilly: or Dr. Barbara Laughon at NIAID.

News Releases

Statement of Christine F. Sizemore, Ph.D., Barbara E. Laughon, Ph.D., and Anthony S. Fauci, M.D., on World TB Day—Mar. 24, 2008

Lilly Unveils Ambitious Partnership for Tuberculosis Drug Discovery—June 13, 2007 (Eli Lilly and Company)

back to top

Last Updated January 03, 2012